Promising COVID-19 Therapeutic Drug to start Phase III Clinical Trial in the United States

Pulmonem, Inc. and the Research Institute of the McGill University Health Centre today announced that they have successfully started recruiting US-based patients for the Phase III Clinical Trial of the promising COVID-19 therapeutic drug PULM-001.